Application of the Gradient Boosted method in randomised clinical trials: Participant variables that contribute to depression treatment efficacy of duloxetine, SSRIs or placebo

Journal of Affective Disorders

Volumn 168, Issue , 2014, Pages 284-293

  Dodd, Seetal ^a,b   Berk, Michael ^a,b,c   Kelin, Katarina ^d   Zhang, Qianyi ^e   Eriksson, Elias ^f   Deberdt, Walter ^g   Craig Nelson, J ^h  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c ORYGEN RESEARCH CENTRE   (Australia)

^d ELI LILLY AUSTRALIA PTY LTD   (Australia)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g Eli Lilly Benelux   (Belgium)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Depression; Duloxetine; Gradient Boosted method; Randomised clinical trial; SSRI

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; THIOPHENE DERIVATIVE;

ACCURACY; ADULT; ANXIETY DISORDER; ARTICLE; DEPRESSION; FEMALE; GRADIENT BOOSTED MODEL; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; DEPRESSIVE DISORDER; META ANALYSIS; MIDDLE AGED;

ADULT; AGED; DEPRESSION; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME;

EID: 84905179046     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.05.014     Document Type: Article

References (33)

1. P. Banerjee, B. Choi, L.K. Shahine, S.H. Jun, K. O'Leary, R.B. Lathi, L.M. Westphal, W.H. Wong, and M.W. Yao Deep phenotyping to predict live birth outcomes in in vitro fertilization Proc. Nat. Acad. Sci. U.S.A. 107 2010 13570 13575
2. S.K. Brannan, C.H. Mallinckrodt, E.B. Brown, M.M. Wohlreich, J.G. Watkin, and A.F. Schatzberg Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder J. Psychiatr. Res. 39 2005 43 53 (Pubitemid 39422285)
3. L. Breiman, J.H. Friedman, R.A. Olshen, and C.J. Stone Classification and Regression Trees 1984 Chapman & Hall/CRC Boca Raton, FL
4. M.J. Detke, Y. Lu, D.J. Goldstein, J.R. Hayes, and M.A. Demitrack Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial J. Clin. Psychiatry 63 2002 308 315 (Pubitemid 34456358)
5. M.J. Detke, Y. Lu, D.J. Goldstein, R.K. McNamara, and M.A. Demitrack Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression J. Psychiatr. Res. 36 2002 383 390 (Pubitemid 35254112)
6. M.J. Detke, C.G. Wiltse, C.H. Mallinckrodt, R.K. McNamara, M.A. Demitrack, and I. Bitter Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial Eur. Neuropsychopharmacol. 14 2004 457 470 (Pubitemid 39626894)
7. T.G. Dietterich Ensemble learning M.A. Arbib, The Handbook of Brain Theory and Neural Networks second ed 2002 The MIT Press Cambridge, MA
8. S. Dodd, and M. Berk Predictors of antidepressant response: a selective review Int. J. Psychiatry Clin. Pract. 8 2004 91 100 (Pubitemid 38833081)
9. J.H. Friedman Greedy function approximation: a gradient boosting machine Ann. Stat. 29 2001 1189 1202
10. Gartlehner, G., Hansen, R.A., Morgan, L.C., Thaler, K., Lux, L.J., Van Noord, M., Mager, U., Gaynes, B.N., Thieda, P., Strobelberger, M., et al., 2011a. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. (Prepared by the RTI International-University of North Carolina Evidence-based Practice Center, Contract no. 290-2007-10056-I.) AHRQ Publication no. 12-EHC012-EF. Rockville, MD: Agency for Healthcare Research and Quality http://www. effectivehealthcare.ahrq.gov/reports/final.cfm.%202011.
11. Gartlehner,G., Hansen, R.A., Morgan, L.C., Thaler, K., Lux, L.J., Van Noord, M., Mager, U., Gaynes, B.N., Thieda, P., Strobelberger, M., et al., 2011b. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.%202011. (Prepared by the RTI International-University of North Carolina Evidence-based Practice Center, Contract no 290-2007-10056-I) AHRQ Publication no 12-EHC012-EF Rockville, MD: Agency for Healthcare Research and Quality
12. D J. Clin. Psychopharmacol. 32 2012 114 119
13. D.J. Goldstein, C. Mallinckrodt, Y. Lu, and M.A. Demitrack Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial J. Clin. Psychiatry 63 2002 225 231 (Pubitemid 34407082)
14. D.J. Goldstein, Y. Lu, M.J. Detke, C. Wiltse, C. Mallinckrodt, and M.A. Demitrack Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine J. Clin. Psychopharmacol. 24 2004 389 399 (Pubitemid 38944137)
15. M. Hamilton Development of a rating scale for primary depressive illness Br. J. Clin. Psychol. 6 1967 278 296
16. T. Hastie, R. Tibshirani, and J.H. Friedman The Elements of Statistical Learning 2001 Springer-Verlag New York, NY
17. C.D. Kilts, A.G. Wade, H.F. Andersen, and T.E. Schlaepfer Baseline severity of depression predicts antidepressant drug response relative to escitalopram Expert Opin. Pharmacother. 10 2009 927 936
18. P. Lee, L. Shu, X. Xu, C.Y. Wang, M.S. Lee, C.Y. Liu, J.P. Hong, S. Ruschel, J. Raskin, S.A. Colman, and G.A. Harrison Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil Psychiatry Clin. Neurosci. 61 2007 295 307 (Pubitemid 46684004)
19. J.M. Martinez, W. Katon, J.H. Greist, K. Kroenke, M.E. Thase, A.L. Meyers, S.E. Edwards, L.B. Marangell, S. Shoemaker, and R. Swindle A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode Int. Clin. Psychopharmacol. 27 2012 17 26
20. J.C. Nelson, Q. Zhang, W. Deberdt, L.B. Marangell, O. Karamustafalioglu, and I.A. Lipkovich Predictors of remission with placebo using an integrated study database from patients with major depressive disorder Curr. Med. Res. Opin. 28 2012 325 334
21. A.A. Nierenberg, J.H. Greist, C.H. Mallinckrodt, A. Prakash, A. Sambunaris, G.D. Tollefson, and M.M. Wohlreich Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study Curr. Med. Res. Opin. 23 2007 401 416 (Pubitemid 46333388)
22. T.M. Oakes, A.L. Myers, L.B. Marangell, J Ahl, A. Prakash, M.E. Thase, and S.G. Kornstein Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol Hum. Psychopharmacol. 27 2012 47 56
23. V. Ozdemir, B. Williams-Jones, D.M. Cooper, T. Someya, and B. Godard Mapping translational research in personalized therapeutics: from molecular markers to health policy Pharmacogenomics 8 2007 177 185
24. D.G. Perahia, F. Wang, C.H. Mallinckrodt, D.J. Walker, and M.J. Detke Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial Eur. Psychiatry 21 2006 367 378
25. D.G. Perahia, Y.L. Pritchett, D.K. Kajdasz, M. Bauer, R. Jain, J.M. Russell, D.J. Walker, K.A. Spencer, D.M. Froud, J. Raskin, and M.E. Thase A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder J. Psychiatr. Res. 42 2008 22 34 (Pubitemid 47570043)
26. J. Raskin, C.G. Wiltse, J.J. Dinkel, D.J. Walker, D. Desaiah, and C. Katona Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder J. Clin. Psychopharmacol. 28 2008 32 38
27. J. Raskin, J.Y. Xu, and D.K. Kajdasz Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder Int. Psychogeriatr. 20 2008 309 327 (Pubitemid 351230223)
28. Ridgeway, G., 2007. Generalized Boosted Models: A Guide to the GBM Package. http://cran.r-project.org/web/packages/gbm/vignettes/gbm.pdf.
29. M. Riedel, H.J. Moller, M. Obermeier, M. Adli, M. Bauer, K. Kronmuller, P. Brieger, G. Laux, W. Bender, and I. Heuser et al. Clinical predictors of response and remission in inpatients with depressive syndromes J. Affect. Disord. 133 2011 137 149
30. M.E. Thase, Y.L. Pritchett, M.J. Ossanna, R.W. Swindle, J. Xu, and M.J. Detke Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder J. Clin. Psychopharmacol. 27 2007 672 676 (Pubitemid 351339455)
31. R. Tranter, C. O'Donovan, P. Chandarana, and S. Kennedy Prevalence and outcome of partial remission in depression J. Psychiatry Neurosci. 27 2002 241 247 (Pubitemid 34988904)
32. M.H. Trivedi, D.W. Morris, J.Y. Pan, B.D. Grannemann, and A. John Rush What moderator characteristics are associated with better prognosis for depression? Neuropsychiatr. Dis. Treat. 1 2005 51 57
33. T.N. Wise, C.G. Wiltse, D.V. Iosifescu, M. Sheridan, J.Y. Xu, and J. Raskin The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity Int. J. Clin. Pract. 61 2007 1283 1293 (Pubitemid 47052377)